Immuneering Corp Cl A IMRX

$3.71 +0.04 (1.09%)

Valuation

Market cap
237,680,000
Revenue TTM
$0
Net income TTM
$-56,020,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
849,100
Avg volume
756,780
Day's range
$3.55 – $3.75
Shares out
64,763,000
Stochastic %K
60%
Beta
0.49
Analysts
Strong Buy
Price target
$17.38

Price

Company profile

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical tri...

Show more

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 500 8080
Website
https://immuneering.com
Address
245 Main Street, Second Floor, Cambridge, United States

Latest news

Stocktwits

axelvento999 Nov 14, 4:13 AM
$IMRX https://letswinpc.org/research/2026-aacr-research-conference/
0 replies
axelvento999 Nov 14, 4:11 AM
$IMRX Clinical Outcomes Expected - Immuneering announced they will present P0 Thyroid Cancer results on 2026-11-18 for Atebimetinib
0 replies
SpittingImage Nov 13, 4:16 PM
$IMRX thank Jensens dong
1 replies
SpittingImage Nov 13, 3:49 PM
$IMRX redonkulous
0 replies
Eruption Nov 13, 2:55 PM
$IMRX The better the news, the bigger the drop. Same old story.
1 replies
axelvento999 Nov 13, 5:00 AM
$IMRX huge: https://x.com/BenZeskind/status/2120888922683093403
0 replies
rickahuna Nov 12, 11:34 PM
$IMRX As Japan is always in the top 5 countries with the highest pancreatic cancer incidence, Astellas makes sense for a clinical trial collaboration. And, atebimetinib gets exposure in Asia without IMRX paying for trials. Win - Win
0 replies
Merlintrader Nov 12, 6:25 PM
$IMRX Latest company news, Nov 12: Immuneering signed a clinical collaboration and supply agreement with Astellas for two CLDN18.2 pancreatic cancer studies using atebimetinib, and plans an IND by year-end for a potentially registrational Phase 2 in anaplastic thyroid cancer. Full $IMRX stock hub: https://www.merlintrader.com/immuneering-corporation-stock-hub/ Not investment advice.
0 replies